Compare CENX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | ICUI |
|---|---|---|
| Founded | 1995 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 1996 | 1992 |
| Metric | CENX | ICUI |
|---|---|---|
| Price | $45.12 | $149.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $41.00 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 2.1M | 235.7K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,525,100,000.00 | $2,320,363,000.00 |
| Revenue This Year | $16.70 | N/A |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | $58.67 | ★ N/A |
| Revenue Growth | ★ 20.15 | N/A |
| 52 Week Low | $13.05 | $107.00 |
| 52 Week High | $52.00 | $173.85 |
| Indicator | CENX | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 48.11 |
| Support Level | $44.62 | $146.85 |
| Resistance Level | $52.00 | $160.29 |
| Average True Range (ATR) | 2.70 | 4.73 |
| MACD | -0.56 | -0.82 |
| Stochastic Oscillator | 8.17 | 16.37 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.